As detailed, the average risk of progression requiring therapy among individuals with clinical CLL-like MBL appears to be about 1–2% per year.(18, 19, 25) Based on this data, we reassure individuals with CLL-like MBL identified in clinical practice that they are at low risk for developing CLL, counsel them regarding symptoms they should watch for (lymphadenopathy, fevers, night sweats, fatigue, weight loss), and recommend annual follow-up by a hematologist/oncologist with a complete blood count.
